By using a candidate gene-driven strategy, the present work shows evidence on the impact of CD5, CD6, and CD166/ALCAM gene variants in the susceptibility and clinical expression of pSS, thus supporting their involvement in pSS pathophysiology. The gene discussed is CD6; the disease is peeling skin syndrome.